Literature DB >> 8659117

Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.

M A Stone-Marschat1, S R Moss, T G Burrage, M L Barber, P Roy, W W Laegreid.   

Abstract

Horses were immunized by inoculation with a vaccinia construct containing a full-length cDNA corresponding to the L2 gene segment of African horsesickness virus type 4(AHSV-4). All immunized horses developed serum neutralizing antibodies prior to challenge with virulent AHSV-4. No ELISA-reactive antibodies were present prior to challenge. A group of four seronegative control horses died after developing clinical signs and lesions typical of the pulmonary form of African horsesickness while the immunized horses were clinically normal. Increases in serum neutralizing and ELISA-reactive antibody titers following challenge indicate that at least some replication of challenge virus occurred in immunized horses. These results demonstrate that AHSV VP2 alone is sufficient to induce a protective immune response in horses and indicate the usefulness of ELISA-reactive antibodies for differentiation of vaccinated and naturally exposed horses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659117     DOI: 10.1006/viro.1996.0304

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Structural insight into African horsesickness virus infection.

Authors:  Violeta Manole; Pasi Laurinmäki; Wouter Van Wyngaardt; Christiaan A Potgieter; Isabella M Wright; Gert J Venter; Alberdina A van Dijk; B Trevor Sewell; Sarah J Butcher
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

Authors:  Javier Castillo-Olivares; Eva Calvo-Pinilla; Isabel Casanova; Katarzyna Bachanek-Bankowska; Rachael Chiam; Sushila Maan; Jose Maria Nieto; Javier Ortego; Peter Paul Clement Mertens
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

3.  Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.

Authors:  Yuta Kanai; Piet A van Rijn; Mieke Maris-Veldhuis; Yuki Kaname; T N Athmaram; Polly Roy
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

4.  Re-parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search.

Authors:  Emma L Fairbanks; Marnie L Brennan; Peter P C Mertens; Michael J Tildesley; Janet M Daly
Journal:  Transbound Emerg Dis       Date:  2022-01-12       Impact factor: 4.521

5.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

6.  Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.

Authors:  Tamara Kusay Jabbar; Eva Calvo-Pinilla; Francisco Mateos; Simon Gubbins; Abdelghani Bin-Tarif; Katarzyna Bachanek-Bankowska; Oya Alpar; Javier Ortego; Haru-Hisa Takamatsu; Peter Paul Clement Mertens; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

7.  Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.

Authors:  Francisco de la Poza; Eva Calvo-Pinilla; Elena López-Gil; Alejandro Marín-López; Francisco Mateos; Javier Castillo-Olivares; Gema Lorenzo; Javier Ortego
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

8.  Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.

Authors:  Berta Alberca; Katarzyna Bachanek-Bankowska; Marta Cabana; Eva Calvo-Pinilla; Elisenda Viaplana; Lorraine Frost; Simon Gubbins; Alicia Urniza; Peter Mertens; Javier Castillo-Olivares
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

9.  Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.

Authors:  Eva Calvo-Pinilla; Francisco de la Poza; Simon Gubbins; Peter Paul Clement Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2015-01-30       Impact factor: 5.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.